Hospital-Treated Gram-Negative Infections – Access & Reimbursement – Detailed, Expanded Analysis (US)
MARKET OUTLOOK
The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens makes GNIs increasingly challenging to treat. Potent antibiotics such as carbapenems are losing efficacy, driving the use of older antibiotics with toxic side effects. New antibiotics—Merck’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere—retain activity against MDRgram-negative pathogens and thus provide a therapeutic alternative, but there are challenges to their use (e.g., price). In addition, the pipeline of new agents that can address the threat of MDR bacteria is populated with candidates from multiple classes. As payers, hospitals, and prescribers balance clinical need with budget constraints, the value proposition for new drugs must be tailored to secure optimal market share in what is fast becoming a crowded segment of the GNItherapymarket.
QUESTIONS ANSWERED
- What attributes must an emerging GNI therapy offer to secure favorable coverage and formulary positioning?
- What do hospital PDs consider the primary drivers and considerations for formulary inclusion of key emerging GNI antibiotics?
- What are the most prescribed antibiotics for GNIs, including therapies for drug-resistant pathogens?
- How do payer policies influence physician prescribing practices?
- What impact will newly approved antibiotics like Vabomere have on the GNI market? How will payers receive value-based pricing of new drugs that address the high unmet need for patients with MDR infections?
PRODUCT DESCRIPTION
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Geography
Survey of 142 U.S. ID specialists and 31 U.S. hospital pharmacy directors (PDs).
Key drugs covered
Avycaz, Zerbaxa, Vabomere, Invanz, Minocin, Teflaro, and other key generic GNI drugs
Content highlights
- Reimbursement and contracting.
- Access and prescribing.
- Special topics.
- Opportunities and challenges for emerging therapies.
Table of contents
- Hospital-Treated Gram-Negative Infections - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement - HT GNI US 2018
Nuno Antunes, D.V.M., Ph.D., is a director on the Infectious, Niche, and Rare Diseases team at Decision Resources Group. Prior to this role, he was a senior analyst on the Global Market Access Insights team, where he served as a lead expert in market access, pricing and reimbursement, health technology assessment, and health policy in Latin American countries. He has extensive experience in the study of mechanisms of antibiotic resistance and in the development of novel antibiotics. He obtained his Ph.D. from the Universidad de Las Palmas de Gran Canaria in Spain.